Skip Navigation



Home » Clinical Trials » Alzheimer's Disease

Clinical Trial Details


Research Study Summary

Patients are needed to participate in a clinical research study of Gantenerumab and Placebo to evaluate Alzheimer's Disease

Research Study Title

A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients


Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.

To Learn more



Both Male and Female


50 to 80 Years

Overall Status


Lead Sponsor

Chugai Pharmaceutical


21 Months

Facility Type



Both Male and Female ages 50 Years to 80 Years

Inclusion Criteria:

  • Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria

  • Meet DSM-IV criteria for Dementia of the Alzheimer type

  • MMSE score : 16 to 26 etc.

Exclusion Criteria:

  • Meet the exclusion criteria of MRI at screening.

  • A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease.


Site Locations (5)

Country State City Zip Facility and Contact
Japan Kansai Kansai region
Akira Chiba
Japan Kanto Kanto region,
Akira Chiba
Japan Kyushu Kyushu region
Akira Chiba
Japan Toakai Tokai region
Akira Chiba
Japan Tohoku Tohoku region
Akira Chiba


NCT ID: NCT01656525

Date Last Changed: August 6, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.